Brief: Prometheus Announces Initiation Of Global Phase 2 Clinical Trial Of PRA023 In Ulcerative Colitis
19/07/2021 13:08
July 19 (Reuters) - Prometheus Biosciences Inc RXDX.O :
* PROMETHEUS BIOSCIENCES ANNOUNCES INITIATION OF GLOBAL
PHASE 2
CLINICAL TRIAL OF PRA023 IN MODERATE-TO-SEVERE ULCERATIVE
COLITIS (UC)
Source text for Eikon: ID:nGNX8kCGB6
Further company coverage: RXDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prometheus Biosciences
See all newsBrief: Prometheus Biosciences - Completed Merger Of Splash Merger Sub, Unit Of Merck & Co
Analysis: Amgen's antitrust woes spur wider pharmaceutical deal fears
William Blair sees FTC suit on Amgen-Horizon deal weighing on biotech M&A sentiment
FTC scrutiny to block Amgen-Horizon deal drags down Seagen, Prometheus
Brief: Prometheus Biosciences Reports First Quarter 2023 Financial Results